Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 2
January 26 2021
Issue Cover

Table of Contents

POINT-COUNTERPOINT

CAR T cells better than BiTEs
Clinical Trials & Observations
John C. Molina,Nirali N. Shah
View Articletitled, CAR T cells better than BiTEs
BiTEs better than CAR T cells
Marion Subklewe
View Articletitled, BiTEs better than CAR T cells

STIMULUS REPORT

Significant differences in single-platelet biophysics exist across species but attenuate during clot formation
Oluwamayokun Oshinowo,Renee Copeland,Yumiko Sakurai,Meredith E. Fay,Brian G. Petrich,Traci Leong,Benjamin Brainard,Wilbur A. Lam
View Articletitled, Significant differences in single-platelet biophysics exist across species but attenuate during clot formation
Supplemental data

SYSTEMATIC REVIEW

A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Sherif M. Badawy,Usman Beg,Robert I. Liem,Sonali Chaudhury,Alexis A. Thompson
View Articletitled, A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort
Clinical Trials & Observations
Song Yao,Qianqian Zhu,Peter D. Cole,Kristen Stevenson,Marian H. Harris,Emily Schultz,Justine M. Kahn,Elena J. Ladas,Uma H. Athale,Luis A. Clavell,Caroline Laverdiere,Jean-Marie Leclerc,Bruno Michon,Marshall A. Schorin,Jennifer J. G. Welch,Stephen E. Sallan,Lewis B. Silverman,Kara M. Kelly
View Articletitled, Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort
Supplemental data

Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography ©2020. All Rights Reserved.

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
Clinical Trials & Observations
Anjali S. Advani,Eric Larsen,Kristina Laumann,Selina M. Luger,Michaela Liedtke,Meenakshi Devidas,Zhiguo Chen,Jun Yin,Matthew C. Foster,David Claxton,Kristin Coffan,Martin S. Tallman,Frederick R. Appelbaum,Harry Erba,Richard M. Stone,Stephen P. Hunger,Jennifer L. McNeer,Mignon L. Loh,Elizabeth Raetz,Naomi Winick,William Carroll,Richard A. Larson,Wendy Stock
View Articletitled, Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Heterozygous mutation SLFN14 K208N in mice mediates species-specific differences in platelet and erythroid lineage commitment
Rachel J. Stapley,Christopher W. Smith,Elizabeth J. Haining,Andrea Bacon,Sian Lax,Vera P. Pisareva,Andrey V. Pisarev,Steve P. Watson,Abdullah O. Khan,Neil V. Morgan
View Articletitled, Heterozygous mutation <em>SLFN14 K208N</em> in mice mediates species-specific differences in platelet and erythroid lineage commitment
Supplemental data

LYMPHOID NEOPLASIA

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Clinical Trials & Observations
Erel Joffe,Yan Leyfman,Esther Drill,Sridevi Rajeeve,Andrew D. Zelenetz,M. Lia Palomba,Craig H. Moskowitz,Carol Portlock,Ariela Noy,Steven M. Horwitz,John F. Gerecitano,Alison Moskowitz,Paul Hamlin,Matthew J. Matasar,Anita Kumar,Connie L. Batlevi,Anas Younes,David J. Straus
View Articletitled, Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
Clinical Trials & Observations
Shaji Kumar,Alan Fu,Ruben Niesvizky,Sundar Jagannath,Ralph Boccia,Noopur Raje
View Articletitled, Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
Supplemental data
Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop
Lucine Fahy,Julien Calvo,Sara Chabi,Laurent Renou,Charly Le Maout,Sandrine Poglio,Thierry Leblanc,Arnaud Petit,André Baruchel,Paola Ballerini,Irina Naguibneva,Rima Haddad,Marie-Laure Arcangeli,Frederic Mazurier,Francoise Pflumio,Benjamin Uzan
View Articletitled, Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop
Supplemental data
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
Clinical Trials & Observations
François Lemonnier,Violaine Safar,Asma Beldi-Ferchiou,Anne-Ségolène Cottereau,Emmanuel Bachy,Guillaume Cartron,Virginie Fataccioli,Laura Pelletier,Cyrielle Robe,Audrey Letourneau,Edoardo Missiaglia,Slim Fourati,Marie-Pierre Moles-Moreau,Alain Delmer,Reda Bouabdallah,Laurent Voillat,Stéphanie Becker,Céline Bossard,Marie Parrens,Olivier Casasnovas,Victoria Cacheux,Caroline Régny,Vincent Camus,Marie-Hélène Delfau-Larue,Michel Meignan,Laurence de Leval,Philippe Gaulard,Corinne Haioun
View Articletitled, Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
Supplemental data
Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2
Clinical Trials & Observations
Satoshi Nishiwaki,Yu Akahoshi,Shuichi Mizuta,Akihito Shinohara,Shigeki Hirabayashi,Yuma Noguchi,Takahiro Fukuda,Naoyuki Uchida,Masatsugu Tanaka,Makoto Onizuka,Yukiyasu Ozawa,Shuichi Ota,Souichi Shiratori,Yasushi Onishi,Yoshinobu Kanda,Masashi Sawa,Junji Tanaka,Yoshiko Atsuta,Shinichi Kako,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation,for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
View Articletitled, Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph<sup>+</sup> ALL during both CR1 and CR2

MYELOID NEOPLASIA

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes
Clinical Trials & Observations
Kensuke Kayamori,Yurie Nagai,Cheng Zhong,Satoshi Kaito,Daisuke Shinoda,Shuhei Koide,Wakako Kuribayashi,Motohiko Oshima,Yaeko Nakajima-Takagi,Masayuki Yamashita,Naoya Mimura,Hans Jiro Becker,Kiyoko Izawa,Satoshi Yamazaki,Satoshi Iwano,Atsushi Miyawaki,Ryoji Ito,Kaoru Tohyama,William Lennox,Josephine Sheedy,Marla Weetall,Emiko Sakaida,Koutaro Yokote,Atsushi Iwama
View Articletitled, DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Rapid removal of phagosomal ferroportin in macrophages contributes to nutritional immunity
Ronald S. Flannagan,Tayler J. Farrell,Steven M. Trothen,Jimmy D. Dikeakos,David E. Heinrichs
View Articletitled, Rapid removal of phagosomal ferroportin in macrophages contributes to nutritional immunity
Supplemental data
Neutrophil specific granule and NETosis defects in gray platelet syndrome
Cathelijn E. M. Aarts,Kate Downes,Arie J. Hoogendijk,Evelien G. G. Sprenkeler,Roel P. Gazendam,Rémi Favier,Marie Favier,Anton T. J. Tool,John L. van Hamme,Myrto A. Kostadima,Kate Waller,Barbara Zieger,Maaike G. J. M. van Bergen,Saskia M. C. Langemeijer,Bert A. van der Reijden,Hans Janssen,Timo K. van den Berg,Robin van Bruggen,Alexander B. Meijer,Willem H. Ouwehand,Taco W. Kuijpers
View Articletitled, Neutrophil specific granule and NETosis defects in gray platelet syndrome
Supplemental data

PLATELETS AND THROMBOPOIESIS

Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel
Justyne E. Ross,Bing M. Zhang,Kristy Lee,Shruthi Mohan,Brian R. Branchford,Paul Bray,Stefanie N. Dugan,Kathleen Freson,Paula G. Heller,Walter H. A. Kahr,Michele P. Lambert,Lori Luchtman-Jones,Minjie Luo,Juliana Perez Botero,Matthew T. Rondina,Gabriella Ryan,Sarah Westbury,Wolfgang Bergmeier,Jorge Di Paola,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel,on behalf of the ClinGen Platelet Disorder Variant Curation Expert Panel
View Articletitled, Specifications of the variant curation guidelines for <em>ITGA2B</em>/<em>ITGB3</em>: ClinGen Platelet Disorder Variant Curation Panel
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension
Andrew J. Jang,Sarah S. Chang,Changwon Park,Choon-Myung Lee,Raymond L. Benza,Michael J. Passineau,Jing Ma,David R. Archer,Roy L. Sutliff,C. Michael Hart,Bum-Yong Kang
View Articletitled, PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension
Supplemental data

THROMBOSIS AND HEMOSTASIS

Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
Clinical Trials & Observations
Dino Mehic,Alexander Tolios,Stefanie Hofer,Cihan Ay,Helmuth Haslacher,Judit Rejtö,Willem H. Ouwehand,Kate Downes,Matthias Haimel,Ingrid Pabinger,Johanna Gebhart
View Articletitled, Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
Supplemental data
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer
Clinical Trials & Observations
Yohei Hisada,Kenison B. Garratt,Anaum Maqsood,Steven P. Grover,Tomohiro Kawano,Brian C. Cooley,Jonathan Erlich,Florian Moik,Matthew J. Flick,Ingrid Pabinger,Nigel Mackman,Cihan Ay
View Articletitled, Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer
Supplemental data
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Jochen Buechner,Stephan A. Grupp,Hidefumi Hiramatsu,David T. Teachey,Susana Rives,Theodore W. Laetsch,Gregory A. Yanik,Patricia Wood,Rakesh Awasthi,Lan Yi,Andrea Chassot-Agostinho,Lamis K. Eldjerou,Barbara De Moerloose
View Articletitled, Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Supplemental data

TRANSFUSION MEDICINE

Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice
Connie M. Arthur,Jerry William L. Allen,Hans Verkerke,Justin Yoo,Ryan P. Jajosky,Kathryn Girard-Pierce,Satheesh Chonat,Patricia Zerra,Cheryl Maier,Jen Rha,Ross Fasano,Cassandra D. Josephson,John D. Roback,Sean R. Stowell
View Articletitled, Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice
Supplemental data

TRANSPLANTATION

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
Benedetta Rambaldi,Haesook T. Kim,Carol Reynolds,Sharmila Chamling Rai,Yohei Arihara,Tomohiro Kubo,Leutz Buon,Mahasweta Gooptu,John Koreth,Corey Cutler,Sarah Nikiforow,Vincent T. Ho,Edwin P. Alyea,Joseph H. Antin,Catherine J. Wu,Robert J. Soiffer,Jerome Ritz,Rizwan Romee
View Articletitled, Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
Supplemental data
Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT
Nobuaki Nakano,Atae Utsunomiya,Keitaro Matsuo,Noriaki Yoshida,Masao Seto,Kouichi Ohshima,Hiroshi Fujiwara,Shigeo Fuji,Yoshifusa Takatsuka,Ayumu Ito,Toshihiro Miyamoto,Youko Suehiro,Hirohisa Nakamae,Yasushi Sawayama,Mitsuhiro Yuasa,Yasuhiko Miyazaki,Shuichi Ota,Kazunori Imada,Takahiro Fukuda,Tatsuo Ichinohe,Yoshiko Atsuta,Koji Kato
View Articletitled, Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT
Supplemental data
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses
Clinical Trials & Observations
Vanessa A. Fabrizio,M. Irene Rodriguez-Sanchez,Audrey Mauguen,Parastoo B. Dahi,Ekaterina Doubrovina,Richard J. O’Reilly,Susan E. Prockop
View Articletitled, Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4<sup>+</sup> immunity to mediate durable responses

COMMENTARY

von Willebrand disease: proposing definitions for future research
Clinical Trials & Observations
Nathan T. Connell,Paula D. James,Romina Brignardello-Petersen,Rezan Abdul-Kadir,Barbara Ameer,Alice Arapshian,Susie Couper,Jorge Di Paola,Jeroen Eikenboom,Nicolas Giraud,Jean M. Grow,Sandra Haberichter,Vicki Jacobs-Pratt,Barbara A. Konkle,Peter Kouides,Michael Laffan,Michelle Lavin,Frank W. G. Leebeek,Claire McLintock,Simon McRae,Robert Montgomery,Sarah H. O'Brien,James S. O'Donnell,Margareth C. Ozelo,Nikole Scappe,Robert Sidonio, Jr,Alberto Tosetto,Angela C. Weyand,Mohamad A. Kalot,Nedaa Husainat,Reem A. Mustafa,Veronica H. Flood
View Articletitled, von Willebrand disease: proposing definitions for future research

ERRATA

Wu Y-J, Hou M, Liu H-X, et al; Cooperative ITP Working Group. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.
View Articletitled, Wu Y-J, Hou M, Liu H-X, et al; Cooperative ITP Working Group. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. <em>Blood Adv.</em> 2020;4(22):5846-5857.
Short NJ, Rafei H, Daver N, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020;4(24):6117-6126.
View Articletitled, Short NJ, Rafei H, Daver N, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <em>Blood Adv.</em> 2020;4(24):6117-6126.
All Issues

Advertisement intended for health care professionals

Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.
Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals